[1]Patent:CN110016052,2019,A.Locationinpatent:Paragraph0055;0063-0068
[1]Backos,DonaldS.;Casalvieri,KimberlyA.;Jordan,CraigT.;Matheson,ChristopherJ.;Minhajuddin,Mohammed;Reigan,Philip[EuropeanJournalofMedicinalChemistry,2020,vol.197]
Title: Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Journal: Biomedical chromatography : BMC 20121101
Title: Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
Journal: Cardiovascular therapeutics 20121001
Title: Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120301
Title: Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110401
Title: Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.
Journal: International journal of clinical pharmacology and therapeutics 20110101
Title: Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
Journal: Cancer chemotherapy and pharmacology 20100901
Title: Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.
Journal: Journal of pharmaceutical and biomedical analysis 20100311
Title: A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Journal: Cancer chemotherapy and pharmacology 20100301
Title: A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091101
Title: A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20090401
Title: Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Journal: Anti-cancer drugs 20060301
Title: Sun L, et al. Discovery of 5--fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor r
Title: Mendel DB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Can
Title: O'Farrell AM, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.
